Bicara Therapeutics (NASDAQ:BCAX) Trading Up 5.6% - Should You Buy?

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) shares were up 5.6% during trading on Monday . The stock traded as high as $12.72 and last traded at $12.84. Approximately 49,869 shares were traded during trading, a decline of 89% from the average daily volume of 469,166 shares. The stock had previously closed at $12.16.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on BCAX. Wells Fargo & Company initiated coverage on Bicara Therapeutics in a research note on Thursday, April 17th. They set an "underweight" rating and a $8.00 price target for the company. Wedbush reiterated an "outperform" rating and set a $31.00 price target on shares of Bicara Therapeutics in a report on Thursday, March 27th. Stifel Nicolaus set a $48.00 target price on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.01 target price on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Finally, HC Wainwright decreased their price objective on Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating on the stock in a report on Monday, April 7th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $32.43.

Bicara Therapeutics Stock Down 7.0 %

The firm's 50-day moving average is $12.79 and its two-hundred day moving average is $16.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.08). On average, analysts expect that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bicara Therapeutics

Large investors have recently modified their holdings of the business. California State Teachers Retirement System bought a new position in Bicara Therapeutics during the fourth quarter worth $25,000. Spire Wealth Management bought a new stake in shares of Bicara Therapeutics in the fourth quarter worth $31,000. BNP Paribas Financial Markets acquired a new stake in shares of Bicara Therapeutics during the fourth quarter worth $32,000. Legal & General Group Plc acquired a new stake in shares of Bicara Therapeutics during the 4th quarter worth approximately $33,000. Finally, Summit Investment Advisors Inc. bought a new position in Bicara Therapeutics in the fourth quarter worth approximately $35,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.